ICAgen Inc. trades in the stock market as ticker ICGN. Business Summary & Profile For ICAgen Inc..

ICAgen Inc.

Icagen, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. It develops ICA-105665 that is in Phase I single dose escalation study in healthy volunteers for epilepsy and neuropathic pain; and Senicapoc, which is in Phase I multiple dose study in healthy volunteers for the treatment of asthma. The company also conducts ongoing drug discovery programs on new therapeutics for pain and inflammatory disorders. Icagen has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma, Inc.; and Pfizer, Inc. The company was founded in 1992 and is based in Dur...
No related news found for this ICAgen Inc..

Write Comment Create Account
The information contained herein does not suggest or imply and should not be construed, in any manner, a guarantee of future performance and/or investment advice.www.nasdaqstockranking.com is not a registered financial advisor or otherwise qualified as investment professional. The content posted here are only the opinion of the poster and should not be taken as recommendations to buy or sell any security or financial instrument. Trading and investing inherently involves the risk of significant loss of money, and can involve the risk of loss of more than the amount invested. Before executing any trade readers are strongly cautioned to consult with a financial adviser of their choosing. www.nasdaqstockranking.com, its affiliates and partners, shall have no liability for investment or other decisions based upon any Content and/or decisions based upon our syndicated page content.
@2012 www.nasdaqstockranking.com - info {at} www.nasdaqstockranking.comContactUs